Table 36Fondaparinux vs LMWH - Clinical summary of findings

OutcomeFondaparinuxLMWHRelative risk (95%) CI)Absolute effectQuality
All cause mortality41/1098
33/1107 (3.0%)1.25 (0.80, 1.97)7 more per 1000 (6 fewer to 29 more)LOW
VTE related mortality5/1098
5/1107 (0.5%)1.01 (0.29, 3.47)0 more per 1000 (3 fewer to 11 more)LOW
Recurrent VTE43/1098
45/1107 (4.1%)0.96 (0.64, 1.45)2 fewer per 1000 (15 fewer to 18 more)LOW
Major bleeding28/1098
26/1107 (2.3%)1.09 (0.64, 1.84)2 more per 1000 (8 fewer to 20 more)LOW
Fatal bleeding5/1098
0/110711.09 (0.61, 200.32)-VERY LOW

From: 7, Pharmacological interventions

Cover of Venous Thromboembolic Diseases
Venous Thromboembolic Diseases: The Management of Venous Thromboembolic Diseases and the Role of Thrombophilia Testing [Internet].
NICE Clinical Guidelines, No. 144.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.